Robert Svatek, MD

Robert S. Svatek, MD, discusses the background and key findings from the SWOG S1602 trial, evaluating BCG strain differences and intradermal BCG before intravesical therapy for patients with BCG-naïve NMIBC.

Robert S. Svatek, MD, MSCI, highlights some of the greatest unmet needs in the non–muscle invasive bladder cancer space.

“The trial is meant to define or test this agent in this population for which currently there's not an established standard of care,” says Robert Svatek, MD.